Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lexaria Study Shows DehydraTECH Outperforms Rybelsus® in Weight Control, Diabetes
Details : Oral DehydraTECH-technology processed liraglutide (GLP-1 agonist) is being investigated for obesity in comparison with Rybelsus (semaglutide).
Brand Name : DehydraTECH-liraglutide
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 20, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Liraglutide,Semaglutide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Details : Oral DehydraTECH-technology processed semaglutide and liraglutide (GLP-1 agonist) is being investigated for obesity.
Brand Name : DehydraTECH-liraglutide
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 24, 2024
Lead Product(s) : Liraglutide,Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Details : DehydraTECH-Liraglutide (liraglutide) is a DehydraTECH-processed GLP-1 receptor agonist, which is being evaluated for the treatment of diabetes and weight loss.
Brand Name : DehydraTECH-liraglutide
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 22, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Liraglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novo's Older Obesity Drug is Safe and Effective for Children, Study Finds
Details : Saxenda is a GLP-1 receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity being investigated for chronic weight management in 6-12 years old patients.
Brand Name : Saxenda
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 10, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Positive Interim Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Details : DehydraTECH-Liraglutide (liraglutide) is a DehydraTECH-processed GLP-1 receptor agonist, which is being evaluated for the treatment of diabetes and weight loss.
Brand Name : DehydraTECH-Liraglutide
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 22, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Liraglutide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novo's Older Obesity Drug Shows Biological Effect on Alzheimer's Patients in Small Trial
Details : Liraglutide-Generic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is investigated for the treatment of patients with mild alzheimer's disease.
Brand Name : Victoza
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 29, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Teva Launches Authorized Generic of Victoza (liraglutide) in the U.S.
Details : Victoza-Generic (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.
Brand Name : Victoza-Generic
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 24, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen
Details : Victoza-Generic (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.
Brand Name : Victoza-Generic
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 13, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
4Moving Biotech Announces Success in Phase I Trial of Liraglutide for Knee Osteoarthritis
Details : 4P004 (intraarticular liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with knee osteoarthritis.
Brand Name : 4P004
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 10, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Liraglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved
Sponsor : Biocon
Deal Size : Undisclosed
Deal Type : Agreement
Biocon Signs Deal for Generic Saxenda® Commercialization in Mexico
Details : Under the agreement, Biocon will obtain regulatory approval and manufacture Saxenda (liraglutide) for chronic weight management, while Medix will commercialize it in Mexico.
Brand Name : Saxenda-Generic
Molecule Type : Peptide
Upfront Cash : Undisclosed
May 13, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Sponsor : Biocon
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?